Related Experiment Videos
[Treatment of multiple myeloma]
1Service d'immuno-hématologie, hôpital Saint-Louis, Paris.
La Revue Du Praticien
|February 1, 1993
Abstract:
The various chemotherapeutic regimens in multiple myeloma allow only a mean survival of less than three years. Polychemotherapy has at best a minor advantage over monochemotherapy. High dose chemotherapy followed by hematopoietic stem cell grafts yields a notable percentage of apparent complete remission. The best therapeutic choices as well as the introduction of new drugs such as alpha interferon still needs prospective evaluation.